BLUE BIOFUELS, INC. 10-Q

10-Q 1 form10-q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarter ended March 31, 2021 Commission File Number: 000-54942 ALLIANCE BIOENERGY PLUS, INC. (Exact name of small Business Issuer as specified in its charter) Nevada 45-4944960 (State or other jurisdiction of (IRS Employer incorporation or organization) Identification No.) 3710 Buckeye Street, Suite 120 Palm Beach Gardens, FL 33410 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: (888) 607-3555 Former address if changed since last report Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Not applicable. Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [ ] No [X] Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes[X] No [ ] Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. Large Accelerated Filer [ ] Accelerated Filer [ ] Non-Accelerated Filer [ ] Emerging Growth Company [ ] Smaller reporting company [X] If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised accounting standards provided to Section 7(a)(2)(B) of the Securities Act. [ ] Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). [ ] Yes [X] No The number of the registrant’s shares of common stock outstanding were 272,311,066 as of May 12, 2021. TABLE OF CONTENTS Page PART I—FINANCIAL INFORMATION ITEM 1. Consolidated Financial Statements (unaudited) 4 ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 23 ITEM 3. Quantitative and Qualitative Disclosures About Market Risk 23 ITEM 4. Controls and Procedures 23 PART II—OTHER INFORMATION ITEM 1. Legal Proceedings 24 ITEM 1A. Risk Factors 25 ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds 25 ITEM 3. Defaults Upon Senior Securities 25 ITEM 4. Mine Safety Disclosures 25 ITEM 5. Other Information 25 ITEM 6. Exhibits 25 Signatures 25 2 PART I – FINANCIAL INFORMATION TABLE OF CONTENTS Index to Financial Statements Page Condensed Consolidated Balance Sheets as of March 31, 2021 (unaudited) and December 31, 2020 4 Condensed Consolidated Statements of Operations for the Three Months Ended March 31, 2021 and 2020 (unaudited) 5 Condensed Consolidated Statements of Stockholders’ Equity for the Three Months Ended March 31, 2021 and 2020 (unaudited) 6 Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2021 and 2020 (unaudited) 7 Notes to Condensed Consolidated Financial Statements (unaudited) 8 3 Alliance BioEnergy Plus, Inc. Financial Statements Period Ended March 31, 2021 UNAUDITED FINANCIAL STATEMENTS OF ALLIANCE BIOENERGY PLUS, INC. January 1, 2021 through March 31, 2021 Alliance BioEnergy Plus, Inc. CONSOLIDATED BALANCE SHEETS (unaudited) March 31, 2021 December 31, 2020 ASSETS Current assets Cash and cash equivalents $ 2,440,403 $ 286,579 Prepaid expenses 78,415 45,324 TOTAL CURRENT ASSETS $ 2,518,818 $ 331,903 Other assets Property and equipment, net of accumulated depreciation and amortization of $239,483 and $231,739 at March 31, 2021 and December 31,2020, respectively 243,107 247,431 Security deposits 30,276 30,276 Right of Use Assets, net of accumulated amortization 125,120 144,876 Patents 142,853 138,016 TOTAL OTHER ASSETS $ 541,356 $ 560,599 TOTAL ASSETS $ 3,060,174 $ 892,502 LIABILITIES AND STOCKHOLDERS’ DEFICIT Current liabilities Accounts payable $ 18,379 $ 90,965 Accounts payable - Related Party 76,670 76,670 Deferred wages and director’s fees - Related party 227,295 676,477 Lease Liability - Current 81,938 80,078 Convertible Debentures — Related Party - 75,000 Interest Payable - Related Party 50,056 99,268 TOTAL CURRENT LIABILITIES $ 454,338 $ 1,098,458 Long term liabilities Right of Use Lease Liability, net of current portion 51,020 72,346 Paycheck Protection Program SBA loan 66,330 66,330 Chapter 11 Settlement 50,000 50,000 Notes Payable — Related Party 2,521,562 2,521,562 Notes Payable — Other 216,570 216,570 Convertible debenture, payable from future profits — Related Party - 204,000 TOTAL LONG TERM LIABILITIES $ 2,905,482 $ 3,130,808 TOTAL LIABILITIES $ 3,359,820 $ 4,229,266 STOCKHOLDERS’ EQUITY Preferred stock; $0.001 par value; 10,000,000 shares authorized; zero shares issued and outstanding - - Common stock; $0.001 par value; 500,000,000 shares authorized; 272,251,066 shares issued and outstanding at March 31, 2021, and 241,721,947 shares issued and outstanding at December 31, 2020. 272,251 241,722 Additional paid-in capital 46,723,780 43,103,607 Accumulated deficit (47,295,677 ) $ (46,682,093 ) Total stockholders’ equity $ (299,646 ) $ (3,336,764 ) TOTAL EQUITY (DEFICIT) $ (299,646 ) $ (3,336,764 ) TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT $ 3,060,174 $ 892,502 4 Alliance BioEnergy Plus, Inc CONSOLIDATED STATEMENT OF OPERATIONS (unaudited) Three Months Ended 31-Mar 2021 2020 Revenues - - Operating expense: General and administrative 306,277 200,034 Research & Development 265,074 90,616 Loss on disposal of assets 33,484 - Total operating expenses 604,835 290,650 Loss from operations: (604,835 ) (290,650 ) Other (income) expense: Interest expense - related party 6,849 105,079 Interest expense - other 1,900 2,126 Total other (income) expense 8,749 107,204 Income (Loss) before provisions for income taxes $ (613,584 ) $ (397,854 ) Provisions for income taxes - - Net Income / (Loss): $ (613,584 ) $ (397,854 ) Net income (loss) per share $ (0.002 ) $ (0.002 ) Weighted average common shares outstanding Basic and Diluted 260,659,019 221,667,958 5 Alliance BioEnergy Plus, Inc. CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (Unaudited) Common Stock Preferred Stock Additional Paid-in Accumulated Total Stockholder’s Shares Amount Shares Amt Capital Deficit (Deficiency) Balance as of December 31, 2019 219,513,233 $ 219,513 - - $ 40,949,645 $ (44,500,966 ) $ (3,331,808 ) Issuance of common stock for services 705,352 705 - - 34,295 - 35,000 Issuance of common stock and warrants for cash through PPM 5,500,000 5,500 - - 269,500 - 275,000 Issuance of 100,000 vested options under the employee, director plan - - 6,431 - 6,431 Net Income (Loss) (397,854 ) (397,854 ) Balance as of March 31, 2020 225,718,585 $ 225,718 - - $ 41,259,871 $ (44,898,820 ) $ (3,413,231 ) Balance as of December 31, 2020 241,721,947 $ 241,722 - - $ 43,103,607 $ (46,682,093 ) $ (3,336,764 ) Issuance of common stock for services 223,000 $ 223 - - $ 46,707 - 46,930 Issuance of 1,166,667 warrants for services - - - 72,090 - 72,090 Warrants exercised 13,455,009 13,455 - - 1,289,362 - 1,302,817 Issuance of common stock and warrants for cash through PPM 9,243,332 9,243 - - 1,926,507 - 1,935,750 Issuance of common stock in exchange for debt 7,080,000 7,080 - - 271,920 - 279,000 Issuance of 10,000 vested options under the employee, director plan - 1,215 1,215 Employee stock options exercised 350,000 350 - - 12,550 - 12,900 Cashless exercise of stock options 177,778 178 - - (178 ) - (0 ) Net Income (Loss) (613,584 ) $ (613,584 ) Balance as of March 31, 2021 272,251,066 272,251 - - 46,723,780 (47,295,677 ) (299,646 ) 6 Alliance BioEnergy Plus, Inc. CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) For the Three Months Ended For the Three Months Ended 31-Mar-21 31-Mar-20 Cash flows from operating activities Net Income (Loss) $ (613,584 ) $ (397,854 ) Reconciliation of net loss to net cash used in operating activities Depreciation and amortization 31,220 29,635 Stock based compensation for services 46,930 35,000 Net Issuance of options and warrants for services 73,305 6,431 Loss on Disposal of assets 33,484 - Changes in operating assets and liabilities Prepaid expenses (33,091 ) 44,618 Accrued interest - related party (49,302 ) 105,079 Accounts payable and accrued liabilities (521,677 ) 33,347 Right of use lease (19,466 ) (18,899 ) Net cash used in operating activities (1,052,181 ) (162,642 ) Cash flows from investing activities Purchase of property and equipment (40,624 ) (44,814 ) Patent Costs (4,838 ) (1,100 ) Net cash from (used in) investing activities (45,462 ) (45,914 ) Cash flows from financing activities Proceeds from exercise of warrants and options 1,315,717 - Net proceeds from issuance of common stock 1,935,750 275,000 Net cash provided by financing activities 3,251,467 275,000 Net increase (decrease) in cash and cash equivalents 2,153,824 66,444 Cash and cash equivalent at beginning of the period 286,579 110,630 Cash and cash equivalent at end of the period $ 2,440,403 $ 177,074 Supplemental disclosure of cash flow information Cash paid during the period for Interest $ - $ - Taxes $ - $ - Supplemental schedule of non-cash activities Cashless conversion of warrants/options $ - $ - Conversion of convertible debenture to common stock $ 279,000 $ - 7 Alliance BioEnergy Plus, Inc. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) NOTE 1 – ORGANIZATION Alliance Bioenergy Plus, Inc (the “Company”) is a technology company focused on emerging technologies in the renewable energy, biofuels, and new technologies sectors. In January 2018, the Company’s technology experts developed a new technology system it calls Cellulose-to-Sugar 2.0 or CTS 2.0, and a patent application was filed. The 100% owned CTS 2.0 is a mechanical/chemical dry process for converting cellulose material into sugar for use in the biofuels industry. CTS 2.0 can convert any cellulosic material – like grasses, wood, paper, farm waste, yard waste, forestry products, energy crops like hemp or King Grass, and the cellulosic portion of municipal solid waste – into sugars and lignin, and subsequently into biofuels and bioplastics. The CTS 2.0 system produces sugar and chemically unmodified lignin among other by-products. The sugar can then be further converted into biofuels and the lignin into bioplastics. The new technology made it worthwhile to financially restructure the Company through Chapter 11. The Company voluntarily filed for Chapter 11 on October 22, 2018, in the U.S. Bankruptcy Court in the Southern District of Florida. The Company exited Chapter 11 on September 18, 2019, while keeping all classes, including shareholders, unimpaired. The bankruptcy case was closed on October 25, 2019. Fresh Start accounting is not being applied because existing voting shares immediately before Plan Confirmation were not less than 50 percent of the voting shares of the emerging entity. The Company’s focus is to commercialize its wholly owned CTS 2.0 technology. The Company is currently working with its 4 th generation prototype and anticipates having a 5 th generation semi-commercial scale system in 2021. Plan of Operation The Company is now doing the engineering work to commercialize its 100% owned CTS 2.0 technology. The Company has a strategy that includes the following: 1) Selling sugar or ethanol either direct or in combination with joint ventures, mergers, and/or acquisitions of existing businesses in the renewable energy space; 2) Selling low-cost high purity lignin, or using that lignin to produce biodegradable plastics, or making biodegradable bioplastics products and selling them under our own brand. NOTE 2 – GOING CONCERN The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles, which contemplate continuation of the Company as a going concern, which assumes the Company will realize its assets and discharge its liabilities in the normal course of business. The Company has not generated any significant revenue since inception and has incurred losses since inception. As of March 31, 2021, the Company has a working capital surplus of $2,064,480. As of March 31, 2021, the Company has incurred accumulated losses of $47,295,677. On October 22, 2018, the Company filed for Chapter 11 bankruptcy. On September 18, 2019, the judge confirmed the Company’s Chapter 11 Plan, and on October 25, 2019, the bankruptcy case was closed. The Company expects to incur significant additional losses and liabilities in connection with its start-up and commercialization activities. The Company’s ability to continue as a going concern is dependent upon its ability to obtain the necessary financing to meet its obligations and repay its liabilities when they become due and to generate sufficient revenues from its operations to pay its operating expenses. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. These financial statements do not include any adjustments related to the recoverability and classifications of recorded asset amounts, or amounts and classifications of liabilities that might result from this uncertainty. There are no assurances that the Company will continue as a going concern. Management believes that the Company’s future success is dependent upon its ability to achieve profitable operations, generate cash from operating activities and obtain additional financing. There is no assurance that the Company will be able to generate sufficient cash from operations, sell additional shares of stock or borrow additional funds. The Company’s inability to obtain additional cash could have a material adverse effect on its financial position, results of operations, and its ability to continue in existence. These financial statements do not include any adjustments that might result from the outcome of this uncertainty The Company intends to raise additional capital and continue engineering work and scaling up towards a full-scale commercial size CTS 2.0 modular unit. At that point, and to minimize dilution to shareholders, the Company will seek project-based financing to build (or acquire and retrofit) or joint venture with existing ethanol producers to produce cellulosic ethanol and lignin/bioplastics from its patented CTS 2.0 system. Once the first plant is profitable, the Company intends to grow with additional plants both in the United States and internationally. Currently, the US government gives a D3 RIN to incentivize the production of renewable fuels from cellulosic materials. The value of the D3 RIN fluctuates, but as of this filing, it is around $2.60 per gallon of ethanol on top of the market price of ethanol. The Company believes that its CTS 2.0 process can produce ethanol profitably at the market price, and with the D3 RIN should generate substantial profits and cash flow in amounts sufficient to cover the Company’s operating expenses and debt service. Our business, results of operations, and financial condition may be adversely impacted by the COVID-19 pandemic . The COVID-19 pandemic has negatively affected the U.S. and global economies, disrupted global supply chains, resulted in significant travel and transport restrictions, including mandated closures and orders to “shelter-in-place,” and created significant disruption of the financial markets. We are closely monitoring the impact of the COVID-19 pandemic on all aspects of our business, including how it will impact our customers, employees and supply chain. Given the critical nature of the products that we provide, our office and lab have remained open during the pandemic. The extent to which our operations may be impacted by the COVID-19 pandemic will depend largely on future developments, which are highly uncertain and cannot be accurately predicted. We may experience additional operating costs due to increased challenges with our workforce (including as a result of illness, absenteeism or government orders), access to supplies, capital, and fundamental support services (such as shipping and transportation). Even after the COVID-19 pandemic has subsided, we may experience materially adverse impacts to our business due to any resulting economic recession or depression. Furthermore, the impacts of a potential worsening of global economic conditions and the continued disruptions to and volatility in the financial markets remain unknown. 8 NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying consolidated financial statements of the Company were prepared in accordance with generally accepted accounting principles in the U.S. (“U.S. GAAP”) and include the assets, liabilities, revenues and expenses of the Company’s majority-owned subsidiaries over which the Company exercises control. Principles of Consolidation The accompanying consolidated financial statements include the accounts of the Company and its subsidiaries, after elimination of intercompany accounts and transactions. Investments in business entities in which the Company lacks control but has the ability to exercise significant influence over operating and financial policies are accounted for using the equity method. All material intercompany transactions and balances were eliminated in consolidation. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the dates presented and reported amounts of revenues and expenses during the reporting periods presented. Significant estimates inherent in the preparation of the accompanying Consolidated Financial Statements include estimates of impairment assessment of identifiable intangible assets and valuation allowance for deferred tax assets. Estimates are based on past experience and other considerations reasonable under the circumstances. Actual results may differ from these estimates. Cash and Cash Equivalents All highly liquid investments with maturities of three months or less at the date of purchase are considered to be cash equivalents. Stock Compensation The Company recognizes the cost of all share-based payments under the relevant authoritative accounting guidance. Share-based payments include any remuneration paid by the Company in shares of the Company’s common stock or financial instruments that grant the recipient the right to acquire shares of the Company’s common stock. For share-based payments to employees, which consist only of awards made under the stock option plan described below, the Company accounts for the payments in accordance with the provisions of ASC Topic 718, “Stock Compensation” (formerly referred to as SFAS No. 123(R)). Share-based payments to consultants, service providers and other non-employees are accounted for in accordance with ASC Topic 718, ASC Topic 505, “Equity Payments to Non-Employees” or other applicable authoritative guidance. Stock-based Compensation Valuation Methodology Stock-based compensation resulting from the issuance of common stock is calculated by reference to the valuation of the stock on the date of issuance, the expense being recognized as the compensation is earned. Stock-based compensation expenses related to employee options and warrants granted to non-employees are recognized as the stock options and warrants are earned. The fair value of the stock options or warrants granted is estimated at the grant date, using the Black-Scholes option-pricing model, and the expense is recognized on a straight-line basis over the shorter of the period over which services are to be received or the life of the option or warrant. The grant date fair value of employee share options and similar instruments is estimated using the Black-Scholes option-pricing model on the basis of the fair value of the underlying common stock on the measurement date, adjusted for the unique characteristics of those equity instruments, using the assumptions noted in the table below. The fair value of the common stock is determined by the then-prevailing closing market price. Expected volatility was based on the historical volatility of the Company’s closing day market price per share. The expected term of options and warrants was based upon the life of the option, and the risk-free rate used was based on the U.S. Treasury Daily Yield Curve Rate. 9 The stock compensation issued for services during the 3 months ended March 31, 2021, was valued on the date of issuance. The following assumptions were used in calculations of the Black-Scholes option pricing models for warrant-based stock compensation issued in the three months ended March 31, 2021: 1/5/21 Risk-free interest rate 0.96 % Expected life 10 years Expected dividends 0 % Expected volatility 209.98 % ALLM common stock fair value $ 0.124 Property and Equipment Property and equipment are stated at cost less accumulated depreciation. Depreciation is provided for on a straight-line basis over the useful lives of the assets, generally 5 to 10 years. Expenditures for additions and improvements are capitalized; repairs and maintenance are expensed as incurred. Patent Capitalization If a product is currently under research and development and is not currently approved for market, costs incurred in connection with patent applications should generally be expensed in the income statement because there is uncertainty as to the future economic benefit of the asset. Conversely, if a product is approved for market (as is the case of the end product ethanol), or if future economic benefit is probable, or if an alternative future use is available to the Company, then such patent costs can be capitalized and amortized over the expected life of the patent(s). Since the Company’s primary end product is sugar converting to ethanol, which are in wide use, the Company has determined that it is reasonable to capitalize the patent costs associated with its CTS process, which were $142,853 as of March 31, 2021 and $138,016 as of December 31, 2020. Research and Development The Company expenses all research and development costs as incurred. For the three months ended March 31, 2021, and March 31, 2020, the amounts charged to research and development expenses were $265,074, and $90,616, respectively. Revenue Recognition The Company follows FASB ASC 605 “Revenue Recognition” and recognizes revenue when it is realized or realizable and earned. The Company’s revenues will be derived principally from joint ventures, royalties and eventually corporate owned plants. However, no sales have occurred through those revenue streams to date. The Company considers revenue realized or realizable and earned when all of the following criteria are met: 1. persuasive evidence of an arrangement exists; 2. the product has been shipped or the services have been rendered to the customer; 3. the sales price is fixed or determinable; and, 4. collectability is reasonably assured. 10 Common Stock Purchase Warrants and Other Derivative Financial Instruments The Company classifies as equity any contracts that require physical settlement or net-share settlement or provide it with a choice of net-cash settlement or settlement in the Company’s own shares (physical settlement or net-share settlement) provided that such contracts are indexed to its own stock as defined in ASC 815-40 (“Contracts in Entity’s Own Equity”). The Company classifies as assets or liabilities any contracts that require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside the Company’s control) or give the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). The Company assesses the classification of its common stock purchase warrants and other free-standing derivatives at each reporting date to determine whether a change in classification between assets and liabilities is required. Non-controlling interest in consolidated subsidiaries The accompanying consolidated financial statements include the accounts of Alliance BioEnergy Plus, Inc. and those subsidiaries that the Company has the ability to control either through voting rights or means other than voting rights. For these subsidiaries, the Company records 100% of the revenues, expenses, cash flows, assets and liabilities in its consolidated financial statements. For subsidiaries that the Company controls but hold less than 100% ownership, a non-controlling interest is recorded in the consolidated income statement to reflect the non-controlling interest’s share of the net income (loss), and a non-controlling interest is recorded in the consolidated balance sheet to reflect the non-controlling interest’s share of the net assets of the subsidiary. Investments in non-consolidated affiliates Investments in non-consolidated affiliates are accounted for using the equity method or cost basis depending upon the level of ownership and/or the Company’s ability to exercise significant influence over the operating and financial policies of the investee. When the equity method is used, investments are recorded at original cost and adjusted periodically to recognize the Company’s proportionate share of the investees’ net income or losses after the date of investment. When net losses from an investment are accounted for under the equity method exceed its carrying amount, the investment balance is reduced to zero and additional losses are not provided for. The Company resumes accounting for the investment under the equity method if the entity subsequently reports net income and the Company’s share of that net income exceeds the share of net losses not recognized during the period the equity method was suspended. Investments are written down only when there is clear evidence that a decline in value that is other than temporary has occurred. Impairment of Long Lived Assets Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable. If events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable, the Company compares the carrying amount of the asset group to future undiscounted net cash flows, excluding interest costs, expected to be generated by the asset group and their ultimate disposition. If the sum of the undiscounted cash flows is less than the carrying value, the impairment to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the fair value of the asset group. Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell. Income Taxes The Company uses the asset and liability method of accounting for income taxes in accordance with ASC Topic 740, “Income Taxes.” Under this method, income tax expense is recognized for the amount of: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity’s financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of the available positive and negative evidence, it is more likely than not some portion or all of the deferred tax assets will not be realized. ASC Topic 740.10.30 clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC Topic 740.10.40 provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. The Company has no material uncertain tax positions for any of the reporting periods presented. 11 Profit (Loss) per Common Share: Basic profit (loss) per share amounts have been calculated using the weighted-average number of common shares outstanding during each reporting period. Diluted loss per share has been calculated using the weighted-average number of common shares plus the potentially dilutive effect of securities such as outstanding options and warrants. The computation of potential common shares has been performed using the treasury stock method. The warrants and options are antidilutive for all periods presented. When net loss is reported, diluted and basic net loss per share amounts are the same as the impact of potential common shares is antidilutive. Fair Value Measurements The Company adopted the provisions of ASC Topic 820, “Fair Value Measurements and Disclosures”, which defines fair value as used in numerous accounting pronouncements, establishes a framework for measuring fair value and expands disclosure of fair value measurements. The estimated fair value of certain financial instruments, payables to related parties, and accounts payable and accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments. ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value: Level 1 — quoted prices in active markets for identical assets or liabilities Level 2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable Level 3 — inputs that are unobservable (for example cash flow modeling inputs based on assumptions) Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that may have an impact on the Company’s accounting and reporting. The Company believes that such recently issued accounting pronouncements and other authoritative guidance for which the effective date is in the future either will not have an impact on its accounting or reporting or that such impact will not be material to its financial position, results of operations, and cash flows when implemented. NOTE 4 – ASSETS Patents The Company has been granted one patent on its technology, has filed for two others, and has also applied for international patents. The Company has capitalized the legal and filing fees in the amount of $142,853 as of March 31, 2021. NOTE 5 – DEBT Convertible Debentures—Related Parties On March 12, 2019, the Company entered into a convertible promissory note with Edmund J Burke for a total of $25,000. The note is due on March 12, 2021, and carries no interest. To the extent unpaid five years after September 18, 2019, it is discharged. At the option of the noteholder, the note is convertible into common stock at $0.025/share. On January 22, 2021, Edmund Burke elected to convert this Note into common stock. 12 On March 12, 2019, the Company entered into a convertible promissory note with AES Capital Partners, LP, for a total of $50,000. The note is due on March 12, 2021, and bears 15% interest. To the extent unpaid five years after September 18, 2019, it is discharged. At the option of the noteholder, the note is convertible into common stock at $0.025/share. Upon conversion, all interest shall be forgiven. On January 22, 2021, AES Capital Partners, LP, elected to convert this Note into common stock. Paycheck Protection Program SBA Loan In May 2020, the Company received a loan in the amount of $66,330 under the Payroll Protection Program (“PPP Loan”). The loan accrues interest at a rate of 1% and has an original maturity date of two years which can be extended to five years by mutual agreement of the Company and SBA. The PPP loan contains customary events of default relating to, among other things, payment defaults and breaches of representations and warranties. Under the terms of the loan, a portion or all of the loan is forgivable to the extent the loan proceeds are used to fund qualifying payroll, rent and utilities during a designated twenty-four-week period. Payments are deferred until the SBA determines the amount to be forgiven. The balance on this PPP loan was $66,330 as of March 31, 2021, and has been classified as a long-term liability in notes payable. On April 21, 2021, the Company received notice that the entire amount is forgiven. Notes Payable – Chapter 11 Settlement On July 18, 2018, the Company’s former Controller Dennis Lenaburg sued the Company for $2,694,577 dollars plus stock warrants in the Circuit Court of the 15 th Judicial Circuit in Palm Beach County, Florida. That lawsuit was moved to the Bankruptcy Court when the Company entered Chapter 11 on October 22, 2018. The Company filed a Complaint against Lenaburg on November 16, 2018, in the bankruptcy court in the Southern District of Florida. The bankruptcy judge ordered mediation, and a settlement was reached that paid Lenaburg $13,650 upon Plan Confirmation and a $50,000 claim payable out of post-confirmation net profits over 3 years, plus 1.5 million common stock warrants with a strike price of $0.30/share and a ten-year expiration period. The $50,000 is due on September 18, 2022. Notes Payable – Related Parties In July 2016, the Company issued six (6) short-term notes payable to related parties in conjunction with the Company’s acquisition of the remaining 49% of AMG Energy Group. These notes had a value of $2,002,126 and accrued interest at a rate of six percent (6%) per annum. As of December 31, 2018, and December 31, 2017, the total interest accrued on the notes was $278,794.68 and $176,460 respectively. All of the notes were due on August 4, 2017 and then were in default. However, the notes were held by related parties with the understanding that the notes were not to be paid until the Company begins generating profit. The Company renegotiated some of these notes during its Chapter 11 proceedings, whereas others failed to submit a claim and were discharged upon the Court’s Confirmation Order approving the Company’s Chapter 11 Plan on September 18, 2019. The renegotiated amounts, as per the Plan Confirmation are all to be paid from 50% of the future net profits and discharged to the extent unpaid five years after the Plan effective date of September 18, 2019. These amount are 1) Mark Koch $240,990 plus 6% interest on any portion not repaid within 12 months of the Company’s first reported quarterly net profit; 2) Animated Family Films $579,942 out of the Company’s net profits plus 6% interest; 3) Steven Dunkle, CTWC, & Wellington Asset Holdings $1.5 million plus 6% interest once there is positive quarterly EBITDA from the first plant of Company, or, at its option, may convert that into an equity investment in the first plant of the Company, measured by a percentage of the total cost to build, subject to a minimum equity interest of 1.25% in said plant. 13 On February 28, 2018, the Company entered into a short-term loan with Steven Sadaka, with a principal balance of $100,000 due and payable on May 1, 2018. The note does not accrue interest, however the Company provided 2,000,000 inducement shares to secure the note. These inducement shares were valued at $84,000 and are being amortized over the life of the note. The note’s maturity date was extended to 7/1/2018. If the note is not repaid at maturity, then an additional 5,000,000 shares of common stock will be due. The note was renegotiated during the Company’s Chapter 11 proceedings, and as per the Plan Confirmation, it is agreed that $100,000 is to be paid out of future gross revenues to satisfy this note in full, with no additional shares to be issued. On May 15, 2018, the Company entered into a short-term loan with Christopher Jemapete, with a principal balance of $50,000 due and payable on May 16, 2019. The note carried an interest rate of 5% plus the company issued 1,250,000 inducement shares to secure the note as well as 1,000,000 warrants with a $0.10 strike price and with a 5-year expiration. These inducement shares were valued at $36,250 and are being amortized over the life of the note; the warrants had a value of $24,449. On August 25, 2018, this note was restructured to remove the warrants. As of June 30, 2018 accrued interest on this note is $315. The note was renegotiated during the Company’s Chapter 11 proceedings, and as per the Plan Confirmation, it is agreed that $50,315.07 is to be paid out of future gross revenues. On May 15, 2018, the Company entered into a short-term loan with Pamela Jemapete, with a principal balance of $50,000 due and payable on May 16, 2019. The note carried an interest rate of 5% plus the company issued 1,250,000 inducement shares to secure the note as well as 1,000,000 warrants with a $0.10 strike price and with a 5-year expiration. These inducement shares were valued at $36,250 and are being amortized over the life of the note; the warrants had a value of $24,449. On August 25, 2018, this note was restructured to remove the warrants. As of June 30, 2018 accrued interest on this note is $315. The note was renegotiated during the Company’s Chapter 11 proceedings, and as per the Plan Confirmation, it is agreed that $50,315.07 is to be paid out of future gross revenues. Notes Payable – Other In July 2016, the Company issued a short-term note payable to a third party in conjunction with the Company’s acquisition of the remaining 49% of AMG Energy Group. The note had a principal balance of $96,570 and accrued interest at a rate of six percent (6%) per annum. As of December 31, 2018, and December 31, 2017, the total interest accrued on the note was $14,382.2 and $8,588 respectively. The note was due on August 4, 2017 and was then in default. The Company renegotiated this note during its Chapter 11 proceedings, and as per the Plan Confirmation, now the $96,570 is to be paid with no interest out of the same 50% of the future net profits of the Company as the notes mentioned above, if any, or discharged to the extent unpaid five years after September 18, 2019. In November 2017, the Company entered into a convertible debenture with Lucas Hoppel, with a principal balance of $143,000 due and payable on May 30, 2018. The note carries an 8% one-time interest charge, a $43,000 original issue discount and a 35% conversion discount to the lowest trade price in the prior twenty-five trading days, after 180 days, in whole or in part at the option of the holder. In addition, the Company provided 500,000 inducement shares to secure the note, and may have to provide additional shares on the note’s 6-month anniversary if the Company’s share price declines. These inducement shares were valued at $39,500 and were amortized over the life of the note. The note can be repaid, without prepayment penalties, within the first 90 days. Thereafter, the note will incur a 120% prepayment penalty of the then outstanding principal and interest due. In May 2018, the company made two principal payments totaling $40,000. The note went into default on June 1, 2018 and incurred a 40% penalty of the outstanding balance immediately prior to the default event. On August 30, 2018, Hoppel sued the Company in Superior Court of the State of California County of San Diego Central District. That case was staid on October 22, 2018 when the Company filed for Chapter 11 protection in the US Bankruptcy Court in the Southern District of Florida. Negotiations took place and a settlement was reached on this note and a subsequent note, and confirmed as part of the Plan Confirmation Order, that Hoppel would be paid a total of $100,000 out of 5% of the future gross revenue of the Company. In February 2018, the Company entered into a convertible debenture with Lucas Hoppel, with a principal balance of $165,000 due and payable on September 21, 2018. The note carries an 8% one-time interest charge, a $15,000 original issue discount and a 40% conversion discount to the lowest trade price in the prior twenty-five trading days, after 180 days, in whole or in part at the option of the holder. In addition, the Company provided 500,000 inducement shares to secure the note. These inducement shares were valued at $14,500, and were amortized over the life of the note. The note can be repaid, without prepayment penalties, within the first 90 days. Thereafter, the note will incur a 120% prepayment penalty of the then outstanding principal and interest due. The Note went into default on June 1, 2018, through a cross default provision with another Note to Hoppel, and incurred a 40% penalty of the outstanding balance immediately prior to the default event. On August 30, 2018, Hoppel sued the Company in Superior Court of the State of California County of San Diego Central District. That case was staid on October 22, 2018 when the Company filed for Chapter 11 protection in the US Bankruptcy Court in the Southern District of Florida. Negotiations took place and a settlement was reached on this note and a prior note, and confirmed as part of the Plan Confirmation Order, that Hoppel would be paid a total of $100,000 out of 5% of the future gross revenue of the Company to settle both notes. 14 On March 27, 2019, the Company entered into an agreement with Partiz and Company, P.A. such that its debt will be reduced from $32,000 to $20,000 payable out of future gross revenues, upon the bankruptcy court’s acceptance of the Company’s plan of reorganization. The Plan was confirmed by the Court on September 18, 2019. Convertible Debentures – Related Parties On November 8, 2018, the Company entered into a convertible promissory note with Edmund J Burke for a total of $175,000. There is no interest, and it is payable out of 20% of the net profits of Company. The note is convertible into common stock at $0.05/share. Upon conversion, Burke shall receive an additional 4,450,148 warrants at a strike price of $0.005/share that expire on November 8, 2023. In addition, 4,450,148 shares of Burke’s common stock was cancelled. On January 22, 2021, Edmund Burke elected to convert this Note into common stock. On November 8, 2018, the Company entered into a convertible promissory note with Steven Sadaka for a total of $24,000. There is no interest, and it is payable out of 2.5% of the net profits of Company. The note is convertible into common stock at $0.05/share. Upon conversion, Sadaka shall receive an additional 1,000,000 warrants at a strike price of $0.005/share that expire on November 8, 2023. In addition, 1,000,000 shares of Sadaka’s common stock was cancelled. On January 15, 2021, Steven Sadaka elected to convert this Note into common stock. On November 8, 2018, the Company entered into a convertible promissory note with Annie Bindler for a total of $2,500. There is no interest, and it is payable out of 0.5% of the net profits of Company. The note is convertible into common stock at $0.05/share. Upon conversion, Annie Bindler shall receive an additional 100,000 warrants at a strike price of $0.005/share that expire on November 8, 2023. In addition, 100,000 shares of Annie Bindler’s common stock was cancelled. On January 13, 2021, Annie Bindler elected to convert this Note into common stock. On November 8, 2018, the Company entered into a convertible promissory note with Zac Bindler for a total of $2,500. There is no interest, and it is payable out of 0.5% of the net profits of Company. The note is convertible into common stock at $0.05/share. Upon conversion, Zac Bindler shall receive an additional 100,000 warrants at a strike price of $0.005/share that expire on November 8, 2023. In addition, 100,000 shares of Zac Bindler’s common stock was cancelled. On January 13, 2021, Zac Bindler elected to convert this Note into common stock. A summary of all debts indicated in the Notes above is as follows: Notes Payable March 31, 2021 December 31, 2020 Short Term Convertible Debentures Related Party $ - $ 75,000 Long Term Chapter 11 Settlement $ 50,000 $ 50,000 Long Term Paycheck Protection Program SBA loan $ 66,330 $ 66,330 Long Term Notes Payable from future revenue — Related Party $ 1,700,630 $ 1,700,630 Long Term Notes Payable from future revenue — Other $ 120,000 $ 120,000 Long Term Note Payable from future profits — Related Party $ 820,932 $ 820,932 Long Term Note Payable from future profits — Other $ 96,570 $ 96,570 Long Term Convertible Debentures — Related Party $ - $ 204,000 TOTAL NOTES $ 2,854,462 $ 3,133,462 Of the $2,854,462 due as of March 31, 2021, $2,738,132 is due out of future revenue or future profits. $2,417,502 of the $2,854,462 will be discharged if not paid by September 18, 2024, which is 5 years after the Company exited Chapter 11. $66,330 has be forgiven by the SBA in April, 2021. The remaining debt that would not be discharged or forgiven is $370,630, consisting of $200,630 due to related parties, and $120,000 due to other, and a $50,000 Chapter 11 settlement. 15 NOTE 6 – STOCKHOLDERS’ EQUITY The total number of shares of capital stock, which the Company has authority to issue, is 510 million, 500 million of which are designated as common stock at $0.001 par value (the “Common Stock”) and 10 million of which are designated as preferred stock par value $0.001 (the “Preferred Stock”). As of March 31,2021, the Company had 272,251,066 shares of Common Stock issued and outstanding and no shares of Preferred Stock were issued. Holders of shares of Common stock shall be entitled to cast one vote for each share held at all stockholders’ meetings for all purposes, including the election of directors. The Common Stock does not have cumulative voting rights. No holder of shares of stock of any class shall be entitled as a matter of right to subscribe for or purchase or receive any part of any new or additional issue of shares of stock of any class, or of securities convertible into shares of stock of any class, whether now hereafter authorized or whether issued for money, for consideration other than money, or by way of dividend. The Company has yet to designate any rights, preferences and privileges for any of its authorized Preferred Stock. For the three months ended March 31, 2021, the Company issued an aggregate of 223,000 shares of its common stock for services valued at $46,930. For the three months ended March 31, 2021, the Company raised $1,935,750 through its private offerings and issued 9,243,332 shares. For the three months ended March 31, 2021, 13,455,009 warrants were executed at an average price of $0.10 cents/share for total proceeds of $1,302,817. For the three months ended March 31, 2021, the Company issued an aggregate of 1,166,667 warrants for services. Using a Black-Scholes asset-pricing model, these warrants were valued at $72,090. They have a 6-month term with exercise prices of 15 cents per share. For the three months ended March 31, 2021, 250,000 employee stock options were exercised using the cashless exercise provision to obtain 177,778 shares. For the three months ended March 31, 2021, 350,000 employee stock options were exercised for proceeds of $12,900. For the three months ended March 31, 2021, 9,913,334 warrants expired. For the three months ended March 31, 2021, the Company issued 20,530,000 employee stock options, 10,000 of which were vested. For the three months ended March 31, 2021, $279,000 of convertible notes issued during Chapter 11 converted into 7,080,000 shares of common stock. NOTE 7 – SEGMENT INFORMATION The Company operates in one segment and does not have any revenue to date. NOTE 8 - COMMITMENTS AND CONTINGENCIES Litigation The Company is subject, from time to time, to litigation, claims and suits arising in the ordinary course of business. On June 21, 2018, Power Up Lending Group Ltd., sued both the Company and four of its managers, ex-managers, and directors of the Company in the United States District Court for the Eastern District of New York. The case was dropped against the Company and the claim discharged by the bankruptcy court upon Plan Confirmation on September 18, 2019. Power Up has continued a tort case against the individuals. The D&O insurance has agreed to cover the CEO Ben Slager, CFO Anthony Santelli, as well as ex-Controller Dennis Lenaburg, in this case. Management believes the Complaint is frivolous and has filed a motion to dismiss which is pending before the Court as of the date of this filing. 16 Leases The Company consolidated its premises into one location on November 1, 2019, and currently leases office and laboratory space in Palm Beach Gardens, FL, that is classified as operating lease right-of-use (“ROU”) assets and operating lease liabilities in the Company’s consolidated balance sheet. ROU assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date for leases exceeding 12 months. The lease period is for twenty-four (24) months from November 1, 2019, to October 31, 2021. This had been extended for one year until October 31, 2022. Annual rent commenced at $84,100 per annum and increases 3% per year. Tenant is also required to cover operating costs that are estimated at $3,084 per month. Operating lease expense is recognized on a straight-line basis over the lease term and is included in General & Administrative expenses. ASC 842 was effective for us beginning January 1, 2019. The adoption had a material impact on our consolidated balance sheets, but did not have a material impact on our consolidated income statements. The most significant impact was the recognition of ROU assets and lease liabilities for operating leases. Rent expense for the three months ending March 31, 2021, and 2020, were $20,045 and $20,054, respectively. The Company recognized the following related to leases in its Consolidated Balance Sheet: YEAR ENDED March 31, 2021 December 31, 2020 Right of Use Lease Liabilities Current portion 81,938 80,078 Long-term portion 51,020 72,346 TOTAL 132,957 152,424 As of March 31, 2021, the total future minimum lease payments in respect of leased premises are as follows: YEAR ENDED MINIMUM DUE 2021 87,056 2022 74,351 2023 0 TOTAL $ 161,407 NOTE 9 – RELATED PARTY TRANSACTIONS Related Party Transactions The Company follows FASB ASC subtopic 850-10, Related Party Disclosures, for the identification of related parties and disclosure of related party transactions. Pursuant to ASC 850-10-20, related parties include: a) affiliates of the Company; b) entities for which investments in their equity securities would be required, absent the election of the fair value option under the Fair Value Option Subsection of Section 825–10–15, to be accounted for by the equity method by the investing entity; c) trusts for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of management; d) principal owners of the Company; e) management of the Company; f) other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and g) other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests. 1) Short-term notes payable, convertible notes, and contingent liabilities issued to related parties are described in NOTE 5. 2) A board resolution was passed on February 13, 2020, that pledged the patents and pending patents to secure the back pay claims of Ben Slager, CEO, Anthony Santelli, CFO, and Charles Sills, Director. This was done to ensure the continued involvement of management to build the Company while they continue to receive less than full salaries. The officers and directors for the Company are involved in other business activities and may, in the future, become involved in other business opportunities. If a specific business opportunity becomes available, such persons may face a conflict in selecting between the Company and their other business interest. The Company has not formulated a policy for the resolution of such conflicts. NOTE 10 – SUBSEQUENT EVENTS The Company has evaluated subsequent events through the date the financial statements were available to be issued. Based on this evaluation, the Company has identified the following subsequent events: From March 31, 2021, through the date of filing, the Company raised $15,000 through its private offerings and issued 60,000 shares. 17 ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION The following discussion should be read in conjunction with the Company’s audited financial statements and the notes thereto. Forward-Looking Statements This quarterly report contains forward-looking statements and information relating to the Company that are based on the beliefs of its management as well as assumptions made by, and information currently available to, its management. When used in this report, the words “believe,” “anticipate,” “expect,” “estimate,” “intend”, “plan” and similar expressions, as they relate to the Company or its management, are intended to identify forward-looking statements. These statements reflect management’s current view of the Company concerning future events and are subject to certain risks, uncertainties and assumptions, including among many others: a general economic downturn; a downturn in the securities markets; federal or state laws or regulations having an adverse effect on proposed transactions that the Company desires to effect; Securities and Exchange Commission regulations which affect trading in the securities of “penny stocks”; and other risks and uncertainties. Should any of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in this report as anticipated, estimated or expected. The accompanying information contained in this registration statement, including, without limitation, the information set forth under the heading “Management’s Discussion and Analysis and Plan of Operation — Risk Factors” identifies important additional factors that could materially adversely affect actual results and performance. You are urged to carefully consider these factors. All forward-looking statements attributable to the Company are expressly qualified in their entirety by the foregoing cautionary statement. Business Overview Alliance Bioenergy Plus, Inc (the “Company”) is a technology company focused on emerging technologies in the renewable energy, biofuels, and bioplastics technologies sectors. In January 2018, the Company’s technology experts developed a technology system it calls Cellulose-to-Sugar or CTS 2.0, and a patent application was filed. CTS 2.0 is a mechanical/chemical dry process for converting cellulose material into sugar for use in the biofuels industry. CTS 2.0 can convert virtually any cellulosic material – like grasses, wood, paper, farm waste, yard waste, forestry products, energy crops like hemp or King Grass, and the cellulosic portion of municipal solid waste – into sugars and subsequently into biofuels and bioplastics without the use of enzymes or liquid acids. CTS 2.0 has a near zero carbon footprint, recycles the water and catalyst, and uses no enzymes, expensive chemicals, or strong acids. At commercial scale, management expects to be able to produce ethanol at a lower cost than any competitor due to the fact that the CTS 2.0 process is uncomplicated and efficient, and that it uses low cost feedstock as compared to corn. The new technology made it worthwhile to financially restructure the Company through Chapter 11. The Company voluntarily filed for Chapter 11 on October 22, 2018, in the U.S. Bankruptcy Court in the Southern District of Florida. Management fought and eliminated millions in debts and disputed debts, and the Company exited Chapter 11 on September 18, 2019, while keeping all classes, including shareholders, unimpaired. Having paid all debts that needed to be paid, the bankruptcy case was closed on October 25, 2019. Fresh Start accounting is not being applied because existing voting shares immediately before Plan Confirmation were not less than 50 percent of the voting shares of the emerging entity. 18 The Company completed its 4 th generation CTS 2.0 prototype system in July 2020, upgraded it in early 2021, and is currently testing it to optimize various parameters towards the engineering and scale up to a commercial size reactor. Plan of Operation The Company’s goal is to develop this CTS 2.0 technology to a commercial scale and then seek to either joint venture or acquire existing bioenergy and ethanol plants to install the CTS technology. To minimize dilution to shareholders, the Company will seek project-based financing to build (or acquire and retrofit) or joint venture with existing ethanol producers to produce cellulosic ethanol and lignin/bioplastics from its patented CTS 2.0 system. Retrofitting existing plants with the CTS 2.0 technology may achieve more rapid commercialization than building new plants. Once the first plant is profitable, the Company intends to grow with additional plants both in the United States and internationally. Currently, the US government gives a D3 RIN to incentivize the production of renewable fuels from cellulosic materials. The value of the D3 RIN fluctuates, but as of this filing, it is around $1.60 per gallon of ethanol on top of the market price of ethanol. The Company believes that its CTS 2.0 process can produce ethanol profitably at the market price, and with the D3 RIN should generate substantial profits and cash flow in amounts sufficient to cover the Company’s operating expenses and debt service. The Company has a strategy that includes using its low-cost high-purity lignin co-product to produce biodegradable bioplastics. The Company has also licensed the Vertimass Process to convert ethanol (from the CTS 2.0 process) into bio-jet fuel. That agreement is subject to confidentiality between the parties. The Company believes that its management and consultants have significant experience in the development of technologies from concept to commercialization. As of this date, the Company has generated $194,319 in revenue, however it has not generated any revenues from its core business. Capital Formation On January 5, 2021, the Company closed a financing at 7.5 cents per share having sold 2,143,332 shares and raised $160,750 from the beginning of the year until January 5 th . In January 2021, the company commenced a new offering of shares of its common stock valued at $0.25 per share. Through the date of filing, the Company has sold 7,160,000 shares for aggregate proceeds of $1,790,000. From January 1, 2021, through the date of filing, the Company issued an aggregate of 223,000 shares of its common stock for services valued at $46,930. 19 From January 1, 2021, through the date of filing, the Company issued an aggregate of 1,166,667 warrants for services. Using a Black-Scholes asset-pricing model, these warrants were valued at $72,090. They have a 6-month term with exercise prices of 15 cents per share. From January 1, 2021, through the date of filing, the Company issued options to its managers and employees to purchase 20,530,000 shares of its common stock for a period of ten years at the exercise price of 15 cents per share. Using a Black-Scholes asset-pricing model, these agreements were valued at $2,543,247. Only 10,000 of these options have vested, with a valuation of $1,215. From January 1, 2021, through the date of filing, 350,000 previously issued options were exercised for proceeds of $12,900. In addition, 250,000 options were exercised on a cashless basis for 177,778 shares. From January 1, 2021, through the date of filing, warrants were exercised, for the purchase of 13,455,009 shares of common stock, at prices ranging from $0.005 to $0.25 per share for total proceeds of $1,302,817. From January 1, 2021, through the date of filing, $279,000 of debt issued during Chapter 11 was exchange for 7,080,000 shares of stock. Going Concern The Company has incurred losses since inception, has a working capital deficiency, and may be unable to raise further capital. At March 31, 2021, the Company had a working capital surplus of $2,064,480 and had incurred accumulated losses of $47,295,677 since its inception. The Company expects to incur significant additional losses in connection with its continued start-up activities. As a result, there is substantial doubt about the Company’s ability to continue as a going concern based upon recurring operating losses and its need to obtain additional financing to sustain operations. The Company’s ability to continue as a going concern is dependent upon its ability to obtain the necessary financing to meet its obligations and repay its liabilities when they become due and to generate sufficient revenues from its operations to pay its operating expenses. Results of Operations Comparison of the three month period ended March 31, 2021(unaudited) to March 31, 2020 For the three months ended March 31, 2021, the Company recognized $0 in revenue as opposed to $0 in 2020. For the three months ended March 31, 2021, the Company’s general and administrative expenses increased by $106,243 to $306,277 from $200,034 in 2020. This increase is primarily the result of a $73,259 increase in consultancy fees and $21,223 in promotion related to financings. Interest expense decreased in the quarter ended March 31, 2021 by $98,455 to $8,749 from $107,204 in 2020. The decrease in 2021 was primarily the result of the Company’s decision in 2020 to pay interest on back pay due, and in 2021 of having paid some of that back pay off. For the three months ended March 31, 2021 the Company recorded non-cash impairments of assets of $33,484, as compared to zero in 2020. This was the result of disposing of laboratory assets no longer in use. Research and development (R&D) costs for the three months ended March 31, 2021 were $265,074, an increase of $174,458 from $90,616 in 2020. The increase in R&D expenses is primarily the result of hiring additional personnel to accelerate the process of commercializing the CTS 2.0 system. 20 Liquidity and Capital Resources Liquidity As of March 31, 2021, the Company had $2,440,403 in cash, and total stockholders’ equity at March 31, 2021, was negative $299,646. As of December 31, 2020, the Company had $286,579 in cash and total stockholders’ equity at December 31, 2020 was negative $3,336,764. Total debt, including advances, accounts payable and other notes payable at March 31, 2021, together with interest payable thereon and contingent liabilities, was $3,359,820 a decrease of $869,446 from December 31, 2020, where it stood at $4,229,266. This decrease is attributable to the conversion of convertible notes and the repayment of the majority of deferred wages. $1,820,630 of the remaining debt was renegotiated to be payable out of future revenue and $917,502 out of future profits and otherwise does not come due. During the fiscal quarter ended March 31, 2021, the Company’s operating activities increased by $314,185 to $604,835 from $290,650. This increase can primarily be attributed to an increase in R&D expenses and expenses related to raising capital as compared to 2020. During the fiscal quarter ended March 31, 2021, the Company’s investing activities used $45,462 in cash. This can be primarily attributed to capitalizing $4,838 in patent costs and $40,624 used to purchase machinery and equipment. During the fiscal quarter ended March 31, 2020, the Company’s investing activities used $45,914. This is primarily due to the purchase of equipment of $44,814. During the fiscal quarter ended March 31, 2021, the Company generated an aggregate of $3,251,467 through its financing activities, which is an increase of $2,976,467 from $275,000 during the fiscal quarter ended March 31, 2020. This increase from the prior year can primarily be attributed to $1,935,750 in the sale of common stock through the Company’s private offerings in 2021, and $1,315,717 in proceeds from the exercise of warrants and options. Capital Resources At this time, the Company has limited liquidity and capital resources. To continue funding its operations, the Company will need to generate revenue or obtain additional financing for current and future operations. The Company anticipates needing around $10 million to optimize and scale up its CTS 2.0 system to be commercially ready. The Company anticipates reaching this stage around 18 months after financing. There is no guarantee that we will achieve this additional funding. As of the date of filing, the Company has raised $3,266,467 in 2021, through the issuance of common stock and the exercise of warrants and options, in addition to $10,998,234 through the end of 2020, for a total of $14,254,701, in addition to capital raised through debt or convertible notes. However, there is no guarantee that the company will be able to raise any additional capital on terms acceptable to the Company. The inability to obtain this funding either in the near term and/or longer term will materially affect the ability of the Company to implement its business plan of operations and jeopardize the viability of the Company. In that case, the Company may need to reevaluate and revise its operations. Equity As of March 31, 2021, shareholders’ equity was negative $299,646. There were 272,251,066 shares of common stock issued and outstanding as of March 31, 2021. There were no preferred shares outstanding. The Company has paid no dividends. Critical Accounting Policies Off-Balance Sheet Arrangements The Company does not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on its financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors. 21 Seasonality The Company’s operating results are not affected by seasonality. Inflation The Company’s business and operating results are not affected in any material way by inflation. Contractual Obligations As a “smaller reporting company” as defined by Item 10 of Regulation S-K, the Company is not required to provide this information. ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK As a “smaller reporting company” as defined by Item 10 of Regulation S-K, the Company is not required to provide information required by this Item. ITEM 4. CONTROLS AND PROCEDURES Evaluation of Disclosure Controls and Procedures We maintain disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act). Disclosure controls and procedures refer to controls and other procedures designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC and that such information is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosure. As required by Rule 13a-15(e) of the Exchange Act, our management has carried out an evaluation, with the participation and under the supervision of our chief executive officer and chief financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as of the end of the period covered by this report. Based upon that evaluation, the Company’s Chief Executive Officer and Chief Financial Officer concluded that the Company’s disclosure controls and procedures were not effective as of March 31, 2021 to a reasonable assurance level because of the material weaknesses described below. Management’s Annual Report on Internal Controls over Financial Reporting Management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f)). The Company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. Under the supervision and with the participation of management, including the Chief Executive Officer and Chief Financial Officer, the Company conducted an evaluation of the effectiveness of the Company’s internal control over financial reporting as of March 31, 2021 using the criteria established in “Internal Control - Integrated Framework” issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”). A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis. In its assessment of the effectiveness of internal control over financial reporting as of March 31, 2021, the Company determined that there were control deficiencies that constituted material weaknesses, as described below. 22 1. We have an Audit Committee, but it does not currently contain an independent financial expert member. – While not being legally obligated to have an audit committee, it is management’s view that such a committee, including a financial expert member, is an utmost important entity level control over the Company’s financial statement. Although we have an Audit Committee, it does not currently include a member that is both a financial expert and considered to be independent of management to provide the necessary oversight over management’s activities. 2. We have inadequate cash controls. Although we have separated cash handling and accounting functions, we do not currently require dual signature on the Company’s bank accounts. 3. The Company has insufficient written policies and procedures for accounting and financial reporting with respect to the requirements and application of US GAAP and SEC disclosure requirements. 4. Although the Company retains copies of all financial data and material agreements and backs them up in the cloud, the rest of the Company’s material agreements may not be. In the event of theft, misplacement, or loss due to fire or other unmitigated factors, it may not be possible for the Company to retain all of its material financial data and agreements. Accordingly, the Company concluded that these control deficiencies resulted in a reasonable possibility that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis by the company’s internal controls. As a result of the material weaknesses described above, management has concluded that the Company did not maintain effective internal control over financial reporting as of March 31, 2021, based on criteria established in Internal Control—Integrated Framework issued by COSO. We intend to address the material weaknesses discussed above as soon as practicable but we can give no assurance that we will be able to do so. Designing and implementing an effective disclosure controls and procedures is a continuous effort that requires us to anticipate and react to changes in our business and the economic and regulatory environments and to devote significant resources to maintain a financial reporting system that adequately satisfies our reporting obligations. The remedial measures that we have taken and plan to take may not fully address the material weaknesses that we have identified, and material weaknesses in our disclosure controls and procedures may be identified in the future. Should we discover such conditions, we intend to remediate them as soon as practicable. We are committed to taking appropriate steps for remediation, as needed. All internal control systems, no matter how well designed, have inherent limitations. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. Changes in Internal Control over Financial Reporting There has been no change in our internal control over financial reporting identified in connection with our evaluation we conducted of the effectiveness of our internal control over financial reporting as of December 31, 2020, that occurred during our fourth fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. This annual report does not include an attestation report of the Company’s registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by the Company’s registered public accounting firm pursuant to temporary rules of the SEC that permit the Company to provide only management’s report in this annual report. 23 PART II - OTHER INFORMATION ITEM 1. LEGAL PROCEEDINGS The Company is subject, from time to time, to litigation, claims and suits arising in the ordinary course of business. As of the date of filing, there are no material claims or suits whose outcomes could have a material effect on the Company’s financial statements. On June 21, 2018, Power Up Lending Group Ltd., sued both the Company and four of its managers, ex-managers, and directors of the Company in the United States District Court for the Eastern District of New York. The case was dropped against the Company and the claim discharged by the bankruptcy court upon Plan Confirmation on September 18, 2019. Power Up has continued a tort case against the individuals. The D&O insurance has agreed to cover the CEO Ben Slager, CFO Anthony Santelli, as well as ex-Controller Dennis Lenaburg, in this case. Management believes the Complaint is frivolous and has filed a motion to dismiss which is pending before the Court as of the date of this filing. ITEM 1A. RISK FACTORS. As a “smaller reporting company” as defined by Item 10 of Regulation S-K, the Company is not required to provide information required by this Item. ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES Below is a list of securities sold by the Company from January 1, 2021, through the date of filing which were not registered under the Securities Act. Entity Date of Investment Title of Security Amount of Securities Sold Consideration Mark Cox 01/05/21 Common Stock 133,333 Purchased @ $0.075 per share Dave Vanchina 01/05/21 Common Stock 200,000 Purchased @ $0.075 per share Pamela McKenna 01/05/21 Common Stock 133,333 Purchased @ $0.075 per share Michael Bozek 01/05/21 Common Stock 135,000 Purchased @ $0.075 per share Sean Edmund Burke 01/05/21 Common Stock 133,334 Purchased @ $0.075 per share Jeffrey Howard 01/05/21 Common Stock 200,000 Purchased @ $0.075 per share Brian Joseph Burke 01/05/21 Common Stock 275,000 Purchased @ $0.075 per share Alexander C Shepard 01/05/21 Common Stock 400,000 Purchased @ $0.075 per share Edmund Burke 01/05/21 Common Stock 266,666 Purchased @ $0.075 per share Conner Thomas Burke 01/05/21 Common Stock 133,333 Purchased @ $0.075 per share Kevin Owen Burke 01/05/21 Common Stock 133,333 Purchased @ $0.075 per share Vestech Securities, Inc. 01/05/21 Common Stock 10,500 Professional Services Bret Williams 01/05/21 Common Stock 59,500 Professional Services Tom Camerlengo 01/11/21 Common Stock 200,000 Exercise of Options Radall Brodsky 01/11/21 Common Stock 333,333 Exercise of Warrants John Lucken 01/11/21 Common Stock 333,334 Exercise of Warrants Mary Lucken 01/11/21 Common Stock 166,667 Exercise of Warrants 24 The Loyalty American Companies, Inc. 01/13/21 Common Stock 333,333 Exercise of Warrants Annie Bindler 01/13/21 Common Stock 50,000 Convertible Debenture Zachary Bindler 01/13/21 Common Stock 50,000 Convertible Debenture SLMJ Rocky Opportunity Trust 01/15/21 Common Stock 480,000 Convertible Debenture Annie Bindler 01/20/21 Common Stock 100,000 Exercise of Warrants Zachary Bindler 01/20/21 Common Stock 100,000 Exercise of Warrants John Allen James 01/20/21 Common Stock 200,000 Purchased @ $0.25 per share Randall Brodsky 01/20/21 Common Stock 80,000 Purchased @ $0.25 per share John E. Lucken Revocable Trust 01/20/21 Common Stock 80,000 Purchased @ $0.25 per share Edmund Burke 01/22/21 Common Stock 3,500,000 Convertible Debenture Edmund Burke 01/22/21 Common Stock 1,000,000 Convertible Debenture AES Capital Partners 01/22/21 Common Stock 2,000,000 Convertible Debenture Frank & Joan Costabile Trust 01/25/21 Common Stock 100,000 Purchased @ $0.25 per share Stacy Costabile 01/25/21 Common Stock 100,000 Purchased @ $0.25 per share Randall Brodsky 01/26/21 Common Stock 80,000 Purchased @ $0.25 per share Mary T. Lucken Revocable Trust 01/26/21 Common Stock 80,000 Purchased @ $0.25 per share John E. Lucken Revocable Trust 01/26/21 Common Stock 80,000 Purchased @ $0.25 per share Bohdan Rudawski Revocable Trust 01/26/21 Common Stock 100,000 Purchased @ $0.25 per share Sam Spector 01/26/21 Common Stock 100,000 Purchased @ $0.25 per share Animated Family Films, Inc 01/26/21 Common Stock 100,000 Purchased @ $0.25 per share Bruce Greenburg Revocable Trust 01/26/21 Common Stock 250,000 Exercise of Warrants Chris Kneppers 01/27/21 Common Stock 50,000 Exercise of Warrants Bill Fitzpatrick 01/27/21 Common Stock 100,000 Professional Services Audie Rolnick 01/27/21 Common Stock 90,000 Purchased @ $0.25 per share Makhulu Holdings, LLC 01/29/21 Common Stock 100,000 Purchased @ $0.25 per share Vecchitto FLP Valori, LLC 01/30/21 Common Stock 900,000 Exercise of Warrants Annie Bindler 02/01/21 Common Stock 100,000 Exercise of Warrants Zachary Bindler 02/01/21 Common Stock 100,000 Exercise of Warrants Adam Langsom 02/01/21 Common Stock 15,000 Exercise of Warrants Marjorie A Fidler & Michael Fidler 02/01/21 Common Stock 100,000 Purchased @ $0.25 per share Gregory Nacron 02/01/21 Common Stock 80,000 Purchased @ $0.25 per share Alexander Dimitrief 02/01/21 Common Stock 75,000 Exercise of Warrants Arthur Lehrhoff 02/01/21 Common Stock 15,000 Exercise of Warrants Bernard Lehrhoff 02/01/21 Common Stock 15,000 Exercise of Warrants Bradley S Schmarak Declaration of Trust 02/01/21 Common Stock 45,000 Exercise of Warrants Bryan I Schwartz Revocable Trust 02/01/21 Common Stock 15,000 Exercise of Warrants Daniel J Hyman 02/01/21 Common Stock 15,000 Exercise of Warrants Daniel Lehrhoff and Patti Lehrhoff Trust 02/01/21 Common Stock 30,000 Exercise of Warrants David Duckler 02/01/21 Common Stock 30,000 Exercise of Warrants Diane S Kahan 02/01/21 Common Stock 15,000 Exercise of Warrants JCH Investments, LLC 02/01/21 Common Stock 75,000 Exercise of Warrants Kenneth M Berman 02/01/21 Common Stock 15,000 Exercise of Warrants 25 Mason Phelps Revocable Trust 02/01/21 Common Stock 75,000 Exercise of Warrants Michael Hochman IRA Rollover 02/01/21 Common Stock 21,000 Exercise of Warrants Randy Abeles 02/01/21 Common Stock 30,000 Exercise of Warrants Monique Miron 02/03/21 Common Stock 50,000 Purchased @ $0.25 per share Russel L. Miron 02/03/21 Common Stock 50,000 Purchased @ $0.25 per share Chris Kneppers 02/05/21 Common Stock 320,000 Exercise of Warrants Tyler & Brett Properties, LLC 02/05/21 Common Stock 100,000 Purchased @ $0.25 per share Matthew & Ashley Beck 02/05/21 Common Stock 100,000 Purchased @ $0.25 per share Capital Consulting, Inc. 02/05/21 Common Stock 100,000 Purchased @ $0.25 per share Gary Noskin 02/05/21 Common Stock 100,000 Purchased @ $0.25 per share Martin Schwimmer 02/05/21 Common Stock 100,000 Purchased @ $0.25 per share Steven C Paul 02/05/21 Common Stock 200,000 Purchased @ $0.25 per share Vecchio Financial, LLC 02/05/21 Common Stock 200,000 Purchased @ $0.25 per share PT7, LLC 02/05/21 Common Stock 800,000 Purchased @ $0.25 per share Julie Kaplan 02/05/21 Common Stock 100,000 Purchased @ $0.25 per share LK Dayton Investments, LLC 02/05/21 Common Stock 200,000 Purchased @ $0.25 per share Randall Brodsky 02/05/21 Common Stock 60,000 Purchased @ $0.25 per share 321Gold, Ltd. 02/05/21 Common Stock 200,000 Purchased @ $0.25 per share Steven Nelson 02/05/21 Common Stock 200,000 Purchased @ $0.25 per share Jason Walkow 02/05/21 Common Stock 40,000 Purchased @ $0.25 per share ANIMATED FAMILY FILMS, INC. 02/08/21 Common Stock 100,000 Purchased @ $0.25 per share Krzysztof Gozdziak 02/08/21 Common Stock 140,000 Purchased @ $0.25 per share John Piper Jr. 02/09/21 Common Stock 50,000 Purchased @ $0.25 per share Edward J Piper 02/09/21 Common Stock 50,000 Purchased @ $0.25 per share M&K Bio LLC 02/09/21 Common Stock 600,000 Purchased @ $0.25 per share Bradley S Schmarak 02/09/21 Common Stock 100,000 Purchased @ $0.25 per share Evelyn Varvitsiotes 02/09/21 Common Stock 40,000 Purchased @ $0.25 per share Paul M Chung Trust 02/09/21 Common Stock 100,000 Purchased @ $0.25 per share Raymond L Leon 02/10/21 Common Stock 250,000 Purchased @ $0.25 per share Anthony S De Leo & Paul De Leo JTWROS 02/11/21 Common Stock 200,000 Purchased @ $0.25 per share Chris Kneppers 02/11/21 Common Stock 130,000 Exercise of Warrants LABRYS FUND 02/12/21 Common Stock 100,000 Exercise of Warrants John D Lane 02/12/21 Common Stock 350,000 Exercise of Warrants John D Lane 02/12/21 Common Stock 362,000 Exercise of Warrants SLMJ Rocky 2017 Opportunity Trust 02/12/21 Common Stock 1,000,000 Exercise of Warrants SLMJ Rocky 2017 Opportunity Trust 02/12/21 Common Stock 1,425,000 Exercise of Warrants SLMJ Rocky 2017 Opportunity Trust 02/12/21 Common Stock 1,815,342 Exercise of Warrants Tom Camerlengo 02/19/21 Common Stock 150,000 Exercise of Options Tom Camerlengo 02/19/21 Common Stock 177,778 Cashless Exercise of Options Chris Kneppers 02/22/21 Common Stock 4,500,000 Exercise of Warrants Mark Monahan 02/22/21 Common Stock 200,000 Purchased @ $0.25 per share Jason Taylor 02/24/21 Common Stock 200,000 Purchased @ $0.25 per share David Gross and Nancy Burgess 02/25/21 Common Stock 200,000 Exercise of Warrants Vestech Securities, Inc. 03/03/21 Common Stock 6,450 Professional Services Bret Williams 03/03/21 Common Stock 36,550 Professional Services Max Assenheimer 03/17/21 Common Stock 10,000 Professional Services Hazel Holdings, LP 03/22/21 Common Stock 1,000,000 Purchased @ $0.25 per share Randall Brodsky 04/12/21 Common Stock 60,000 Purchased @ $0.25 per share 26 The securities issued in the above-mentioned transactions were issued in connection with private placements exempt from the registration requirements of Section 5 of the Securities Act of 1933, as amended, pursuant to the terms of Section 4(a)(2) of that Act and Rules 504 and 506 of Regulation D. ITEM 3. DEFAULTS UPON SENIOR SECURITIES None. ITEM 4. MINE SAFETY DISCLOSURES Not applicable. ITEM 5. OTHER INFORMATION None. ITEM 6. EXHIBITS The exhibits listed below are filed as part of or incorporated by reference in this report. Exhibit No. Identification of Exhibit 31.1. Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 31.2 Certification of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 32.1 Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 32.2 Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 27 SIGNATURES Pursuant to the requirements of Section 13 or 15(d) of the Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Alliance BioEnergy Plus, Inc. (Registrant) By /s/ Benjamin Slager Benjamin Slager Chief Executive Officer, (Principal Executive Officer) Date May 17, 2021 By /s/ Anthony Santelli Anthony Santelli Chief Financial Officer (Principal Financial and Accounting Officer) Date May 17, 2021 28